// App-Quantinova.ai

AB0470 : EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) - ONE-YEAR FOLLOW-UP STUDY USING MEPOLIZUMAB ANTI-IL5 THERAPY AS A STEROID SPARING THERAPEUTIC APPROACH

Researchers

Presenter

  • A. Egan

Principal Investigators

  • P. Sivasothy

  • R. Gore

  • M. Martinez Del-Pero

  • C. Owen

  • L. Willcocks

  • R. Smith

  • S. Burns

  • D. Jayne

Medical Centers

  • Addenbrooke’s Hospital, The Vasculitis and Lupus Centre, Cambridge, United Kingdom

  • Addenbrookes Hospital, Department of Paediatrics, Cambridge, United Kingdom

  • Addenbrookes Hospital, Department of Paediatrics, Cambridge, United Kingdom

  • Addenbrooke’s Hospital, The Vasculitis and Lupus Centre, Cambridge, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Eosinophilic granulomatosis with polyangiitis

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • ChemoCentryx, Inc.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved